Gilead Heightens Inflammatory Disease Focus With Second Genome Microbiome Deal

4 hours ago | Xconomy

Gilead Sciences has signed an agreement with South San Francisco biotech Second Genome to use its microbiome drug development expertise to advance the compounds it is...
Read more ...

Organovo Future Unclear After Shareholders Reject Tarveda Merger

8 hours ago | Xconomy

A planned merger between struggling 3-D “bioprinter” Organovo and Tarveda Therapeutics, a privately held cancer drug developer looking to join the public markets through a...
Read more ...

Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics

13 hours ago | Xconomy

Some diseases have proven difficult to address using conventional tools of drug discovery that target disease-causing proteins. Roche is placing a $190 million bet on Arrakis...
Read more ...

Keros Therapeutics Raises $96M in Upsized IPO to Fuel Clinical Tests

17 hours ago | Xconomy | 2 articles

The financial markets may remain volatile but Keros Therapeutics managed to raise more money in its public market debut than it had initially planned. Late Tuesday the...
Read more ...

Sage Restructuring Halves Staff, Turns Focus to Failed Depression Drug

22 hours ago | Xconomy

Sage Therapeutics is cutting workers who sell its only commercialized drug in a corporate reorganization that it says allows it to focus on clinical-stage compounds, including...
Read more ...

Inovio Begins Experimental COVID-19 Vaccine Tests in Healthy Volunteers

22 hours ago | Xconomy

Inovio Pharmaceuticals, one of the biotechs developing a vaccine to prevent COVID-19, has received the FDA's OK to start testing its candidate in healthy volunteers. The...
Read more ...

Creating Consistent Value in Biotech Without Diluting Stakeholders

1 day ago | Xconomy

One of the greatest challenges for pre-commercial biotech companies is consistently generating capital necessary for operating costs and for R&D of new products that provide...
Read more ...

Interactive, Online Xcelerating Life Sciences Boston Event Set for May 13

1 day ago | Xconomy

In the Boston biotech hub, much progress has been made advancing digital health, but significant scientific, technological, financial, and regulatory challenges remain. Join us...
Read more ...

Menlo's Itching Drug Racks Up Two More Trial Failures, Program Ends

2 days ago | Xconomy

An itching drug that was a key part of the merger of Menlo Therapeutics and Foamix Pharmaceuticals has failed two late-stage studies, leading to a halt on further development...
Read more ...

Millendo May Restructure After Prader-Willi Drug Fails Pivotal Test

2 days ago | Xconomy

Millendo Therapeutics is considering a corporate reorganization after its lead drug, an investigational treatment for a rare genetic condition characterized by unrelenting...
Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Keros Therapeutics Raises $96M in Upsized IPO to Fuel Clinical Tests

The financial markets may remain volatile but Keros Therapeutics managed to raise more money in its public market debut than it had initially planned. Late Tuesday the... Read more ...

Gilead Heightens Inflammatory Disease Focus With Second Genome Microbiome Deal

Gilead Sciences has signed an agreement with South San Francisco biotech Second Genome to use its microbiome drug development expertise to advance the compounds it is... Read more ...

Organovo Future Unclear After Shareholders Reject Tarveda Merger

A planned merger between struggling 3-D “bioprinter” Organovo and Tarveda Therapeutics, a privately held cancer drug developer looking to join the public markets through a... Read more ...

In Battle Against COVID-19 Pandemic, Scientists Turn to PacBio Sequencing

Image by Miroslava Chrienova from Pixabay Our team is proud to announce that PacBio has been working closely with customers to help in the fight against the COVID-19 pandemic... Read more ...

Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics

Some diseases have proven difficult to address using conventional tools of drug discovery that target disease-causing proteins. Roche is placing a $190 million bet on Arrakis... Read more ...

Inovio Begins Experimental COVID-19 Vaccine Tests in Healthy Volunteers

Inovio Pharmaceuticals, one of the biotechs developing a vaccine to prevent COVID-19, has received the FDA's OK to start testing its candidate in healthy volunteers. The... Read more ...

Sage Restructuring Halves Staff, Turns Focus to Failed Depression Drug

Sage Therapeutics is cutting workers who sell its only commercialized drug in a corporate reorganization that it says allows it to focus on clinical-stage compounds, including... Read more ...

Creating Consistent Value in Biotech Without Diluting Stakeholders

One of the greatest challenges for pre-commercial biotech companies is consistently generating capital necessary for operating costs and for R&D of new products that provide... Read more ...

Interactive, Online Xcelerating Life Sciences Boston Event Set for May 13

In the Boston biotech hub, much progress has been made advancing digital health, but significant scientific, technological, financial, and regulatory challenges remain. Join us... Read more ...

Community Health Watch Study to Enhance the COVID-19 Pandemic Response

We're facing times that many of us could never have imagined due to COVID-19. We want to improve how health care systems respond to pandemics. Through the “Pandemic Response... Read more ...